BlueCrest Capital Management’s Eli Lilly LLY Stock Holding History

BlueCrest Capital Management’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,635	Closed	-$21.1M	–	264
2025 Q4	$21.1M	Sell	19,635 -30,868	-61%	-$29.5M	0.63%	25
2025 Q3	$38.5M	Buy	50,503 +41,166	+441%	+$30.6M	0.87%	22
2025 Q2	$7.28M	Buy	+9,337	New	+$7.26M	0.28%	39
2024 Q1	–	Sell	-6,098	Closed	-$4.34M	–	250
2023 Q4	$3.55M	Buy	6,098 +2,349	+63%	+$1.37M	0.14%	118
2023 Q3	$2.01M	Buy	3,749 +1,482	+65%	+$764K	0.09%	138
2023 Q2	$1.06M	Buy	+2,267	New	+$951K	0.04%	144
2019 Q4	–	Sell	-11,935	Closed	-$1.33M	–	488
2019 Q3	$1.33M	Buy	+11,935	New	+$1.33M	0.09%	158
2019 Q2	–	Sell	-46,268	Closed	-$6M	–	775
2019 Q1	$6M	Buy	46,268 +35,329	+323%	+$4.3M	0.24%	64
2018 Q4	$1.27M	Buy	10,939 +1,095	+11%	+$122K	0.07%	179
2018 Q3	$1.06M	Buy	9,844 +472	+5%	+$47.2K	0.03%	425
2018 Q2	$800K	Buy	+9,372	New	+$770K	0.02%	612
2018 Q1	–	Sell	-243,108	Closed	-$20.5M	–	1570
2017 Q4	$20.5M	Buy	+243,108	New	+$20.7M	0.56%	24

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlueCrest Capital Management's LLY Position: Q1 2026 in Review

BlueCrest Capital Management sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 19,635 shares — an estimated $21.1M sold.

BlueCrest Capital Management first reported a position in LLY in Q4 2017 and held it in 12 quarters. The position peaked at $38.5M in Q3 2025. 4,379 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

BlueCrest Capital Management reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
BlueCrest Capital Management sold 19,635 Eli Lilly shares in Q1 2026, an estimated $21.1M.
BlueCrest Capital Management first reported a position in Eli Lilly in Q4 2017 and held it in 12 quarters.
BlueCrest Capital Management's Eli Lilly position peaked at $38.5M in Q3 2025.
4,379 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on BlueCrest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.